Scientific Publications
-
Read More
Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.
Hompesch M, Kang J, Han O, Trautmann M, Sorli C, Ogbaa I, Stewart J, Morrow L.BMJ Open Diabetes Research and Care 2021;9:e002208. doi: 10.1136/bmjdrc-2021-002208. -
Read More
Pharmacokinetic and Pharmacodynamic Bioequivalence between regular human insulin [rDNA origin] in 0.9% sodium chloride ready-to-use infusion 1U/mL and in 100U/mL concentrate diluted to 1U/mL in Healthy Males.
Hompesch M, Hawryluk A, Hernandez M, Uchil B, Wilmington A, Peterson L.Diabetes Obes Metab. 2021 Aug 10. doi: 10.1111/dom.14520. -
Read More
TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial.
Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, Rahimi RS, Harrison SA, Ajmera V, Wayne JD, O'Farrell M, McCulloch W, Grimmer K, Rinella M, Wai-Sun Wong V, Ratziu V, Gores GJ, Neuschwander-Tetri BA, Kemble G.Gastroenterology. 2021 Jul 20:S0016-5085(21)03276-5. doi: 10.1053/j.gastro.2021.07.025. -
Read More
Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.
Hompesch M, Kang J, Han O, Trautmann ME, Sorli CH, Ogbaa I, Stewart J, Morrow L.BMJ Open Diabetes Res Care. 2021 Jun;9(1):e002208. doi: 10.1136/bmjdrc-2021-002208 -
Read More
Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients.
Baker B, Schaeffler B, Hirman J, Hompesch M, Pederson S, Smith J.Endocrinol Diab Metab. 2021 Feb 2. doi: 10.1002/edm2.217 -
Read More
Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non-alcoholic fatty liver disease: results from two early phase randomized trials.
Beysen C, Schroeder P, Wu E, Brevard J, Ribadeneira M, Lu W, Dole K, O'Reilly TE, Morrow L, Hompesch M, Hellerstein MK, Li K, Johansson L, Kelly PF.Diabetes Obes Metab. 2020 Dec 2. doi: 10.1111/dom.14272. -
Read More
Customized Programs for Clinical Development and Global Regulatory Services
-
Read More
Expediting NASH Clinical Trials and Biomarker Research: NASH PASS®, a Growing Clinical Research and Patient Registry Platform
-
Read More
Becoming a NASH PASS® Clinical Trial Site for NAFLD and NASH
-
Read More
Pharmacokinetic and Dose-Finding Studies on Efpeglenatide in Patients With Type 2 Diabetes
Kun-Ho Yoon, Jahoon Kang, Se Chang Kwon, Michael E Trautmann, Marcus Hompesch, John Stewart, Christopher H SorliDiabetes Obes Metab . 2020 Aug;22(8):1292-1301. doi: 10.1111/dom.14032. Epub 2020 Apr 4. -
Read More
184 Insulin Sensitivity and Glucose Metabolism of Olanzapine and Combination Olanzapine and Samidorphan: A Phase 1 Exploratory Study in Healthy Volunteers
William Martin, Christine Graham, Linda Morrow, Carine Beysen, Frederico G S Toledo, Daiva Bajorunas, Ying Jian, Bernard Silverman, David McDonnell, Mark N Namchuk, John W NewcomerCNS Spectr . 2020 Apr;25(2):316. doi: 10.1017/S1092852920000991. -
Read More
Clinical Research Strategies to Drive Advances in Obesity Drug Development
-
Read More
Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption
Powell DR, Zambrowicz B, Morrow L, Beysen C, Hompesch M, Turner S, Hellerstein M, Banks P, Strumph P, Lapuerta PJ Clin Endocrinol Metab. 2019 Dec 14. pii: dgz258. doi: 10.1210/clinem/dgz258. -
Read More
NASH Clinical Drug Development – Imaging the Liver and Beyond
-
Read More
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide
Rosenstock J, Sorli CH, Trautmann ME, Morales C, Wendisch U, Dailey G, Hompesch M, Choi IY, Kang J, Stewart J, Yoon KHDiabetes Care. 2019 Jul 18. pii: dc182648. doi: 10.2337/dc18-2648. [Epub ahead of print] -
Read More
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study
Pratley RE, Kang J, Trautmann ME, Hompesch M, Han O, Stewart J, Sorli CH, Jacob S, Yoon KHDiabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13824. [Epub ahead of print] -
Read More
Assessment of Glucose Fluxes Using Stable-Isotope Methods
-
Read More
Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption
Powell D, Zambrowicz B, Morrow L, Beysen C, Hompesch M, Turner S, Hellerstein M, Banks P, Strumph P, Lapuerta P.Presentation at the Endocrine Society Annual Meeting, New Orleans, LA. 2019 Mar 25. -
Read More
Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease: A Focus on Early Phase Clinical Drug Development.
Krentz, Andrew J., Christian Weyer and Marcus Hompesch, editors.Springer International Publishing, 2019. DOI: 10.1007/978-3-030-11748-1. -
Read More
Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes
Hompesch M, Patel DK, LaSalle JR, Bolli GBPostgrad Med. 2019 Jan 29. doi: 10.1080/00325481.2019.1568136. -
Read More
Relationship Between Controlled Attenuation Parameter (CAP) and Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) in Subjects at High Risk for Nonalcoholic Fatty Liver Disease (NAFLD)
Heidi Guthrie, Natalia Castro, Carine Beysen, Linda Morrow and Marcus HompeschPoster presented at the NASH-TAG Conference, Park City, UT. 2019 Jan 3-5. -
Read More
Exploring the insulin secretory properties of the PGD2-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients.
Skrtic S, Tyrberg B, Broberg M, Ericsson H, Schnecke V, Kjaer M, Hompesch M, Andersson EM, Ryberg E, Aivazidis A, Wennberg Huldt C, Löfgren L, Morrow L, Parkinson J, Rydén-Bergsten T, Watkins E, Sörhede Winzell M.PLoS One. 2018 Dec 17;13(12):e0208998. doi: 10.1371/journal.pone.0208998. -
Read More
Non-Invasive Methods for the Assessment of Hepatic Steatosis in NAFLD/NASH Trials
-
Read More
NASH Drug Development Strategies
-
更多资讯
NASH药物开发策略
-
Read More
Pathophysiology of cardiovascular disease in diabetes mellitus.
Rodriguez-Araujo G, Nakagami H.Cardiovascular Endocrinology & Metabolism 2018, 7:4–9 -
Read More
Assessing the Cardiovascular Safety of Novel Diabetes and Obesity Medications – Implications for Early Phase Development
-
Read More
Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development.
Krentz, Andrew J., Lutz Heinemann and Marcus Hompesch, editors.Springer-Verlag London, 2015. DOI: 10.1007/978-1-4471-4920-0. -
Read More
Clinical R&D Services for Metabolic Diseases
-
Read More
Application of a non-invasive integrated screening algorithm to improve enrollment in NAFLD/NASH clinical trials.
Rodriguez-Araujo G, Hernandez M, Morrow L, Millán L, Martínez-Arranz I, Hompesch M.American Diabetes Association Scientific Sessions. 2018 June 22-25. -
更多资讯
代谢性疾病的临床研究开发服务
-
Read More
Hepatic De Novo Lipogenesis Assessment
-
Read More
Importance of assessing the entire liver in MRI-PDFF studies of liver fat.
Johansson L, Hompesch M, Sundbom M, Edholm D, Hockings P, Kullberg J.Global NASH Summit. 2018 Apr 23-25 -
Read More
Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
Crutchlow M, Palcza J, Mostoller K, Mahon C, Barbour A, Marcos M, Xu Y, Watkins E, Morrow L, Hompesch M.Diabetes Obes Metab. 2018 Feb. DOI: 10.1111/dom.13084 -
Read More
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals.
Garito T, Roubenoff R, Hompesch M, Morrow L, Gomez K, Rooks D, Meyers C, Buchsbaum MS, Neelakantham S, Swan T, Filosa LA, Laurent D, Petricoul O, Zakaria M.Diabetes Obes Metab. 2018 Jan;20(1):94-102. doi: 10.1111/dom.13042 -
Read More
Significant improvement of blood glucose control in a high-risk population of type 1 diabetes using a mobile health app – a retrospective observational study.
Hompesch M, Kalcher K, Debong F, Morrow L.American Diabetes Association Scientific Sessions. 2017 June 10. -
Read More
Cardiovascular outcome trials of diabetes and obesity drugs: implications for conditional approval and early phase clinical development.
Krentz AJ, Rodriguez-Araujo, GPharmaceutical Medicine. 2017 Dec; vol 31, issue 6: 399-421 -
Read More
Liver Fat Quantification Using MRI for Assessment of NAFLD/NASH
-
Read More
Leveraging a clinical phase Ib proof-of-concept study for the GPR40 agonist MK-8666 in patients with type 2 diabetes for model-informed phase II dose selection.
Morrow L.Clin Transl Sci. 2017 Jun. doi: 10.1111/cts.12479 -
Read More
Glucose: archetypal biomarker in diabetes diagnosis, clinical management and research.
Krentz AJ, Hompesch M.Biomark Med. 2016 Oct 13 -
Read More
Development Considerations for Biosimilar Insulin Delivery Devices
-
Read More
Hyperinsulinemic Euglycemic Insulin Sensitivity Clamp
-
Read More
Recruitment Considerations for Early Phase Clinical Trials in Diabetes
-
Read More
Oral Glucose Tolerance and Mixed Meal Tolerance Tests
-
Read More
Considerations for Evaluating the Cardiovascular Safety of Novel Treatments for Diabetes
-
Read More
Hypoglycemic Clamp Studies
-
Read More
Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin.
Heinemann L, Baughman R, Boss A, Hompesch M.J Diabetes Sci Technol. 2017 Jan;11(1):148-156. doi: 10.1177/1932296816658055. -
Read More
Graded Glucose Infusion for Assessment of β-Cell Function
-
Read More
Euglycemic Time-Action Profile Glucose Clamps
-
Read More
Introduction to Glucose Clamps: Automated Versus Manual Techniques
-
Read More
Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.
Krentz AJ, Fujioka K, Hompesch MDiabetes Obes Metab. 2016 Jun;18(6):558-70. doi: 10.1111/dom.12657. -
Read More
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.
Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, Yu R, Singleton W, Baker BF, Bhanot S, Crooke RMDiabetes Care. 2016 Aug;39(8):1408-15. doi: 10.2337/dc16-0126 -
Read More
Glucodynamics of Long-Acting Basal Insulin Peglispro (BIL) Compared With Insulin Glargine at Steady State in Subjects with Type 1 Diabetes: substudy of a randomized crossover trial.
Morrow LA, Hompesch M, Jacober SJ, Leng Choi S, Qu Y, Sinha VPDiabetes Obes Metab. 2016 Nov;18(11):1065-1071. doi: 10.1111/dom.12691 -
Read More
Considerations in biosimilar insulin device development
Fry A, Krentz A, Hompesch MBiosimilars. 2016 February 16. Volume 2016:6 Pages 9—15 -
Read More
Metabolic Pharmacotherapy for NAFLD/NASH: A Collaborative Approach to Finding New Treatments
-
Read More
Biosimilar insulins: current and future perspectives
Hompesch M, Krentz AJDiabetes Manag. 2015 5(6), 405-409. doi: 10.2217/dmt.15.33. -
Read More
Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects
de la Peña A, Yeo KP, Linnebjerg H, Catton E, Reddy S, Brown-Augsburger P, Morrow L, Ignaut DAJ Diabetes Sci Technol. 2015 Jul;9(4):824-30. doi: 10.1177/1932296815573865. -
Read More
Biosimilar insulins: guidance for data interpretation by clinicians and users.
Heinemann L, Home PD, Hompesch M.Diabetes, Obesity and Metabolism. 2015 May 13. doi: 10.1111/dom.12491. -
Read More
Anti-Obesity Pharmacotherapy: The Intercontinental Regulatory Divide
Krentz AJ, Fujioka K, Hompesch M.Drugs. 2015 May 12. doi: 10.1007/s40265-015-0404-z. -
Read More
Steady state is reached within two to three days of once-daily administration of degludec, a basal insulin with an ultra-long duration of action
Heise T, Korsatko S, Nosek L, Coester HV, Deller S, Roepstorff C, Segel S, Kapur R, Haahr H, Hompesch M.J Diabetes. 2015 Jan 12. doi: 10.1111/1753-0407.12266. -
Read More
Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.
Hompesch M, Jones-Leone A, Carr MC, Matthews J, Zhi H, Young M, Morrow L, Reinhardt RR.Diabetes Obes Metab. 2015 Jan; 17(1):82-90. doi: 10.1111/dom.12398. -
Read More
Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
Krentz AJ, Morrow L, Petersson M, Norjavaara E, Hompesch M.Diabetes Obes Metab. 2014 Nov;16(11):1096-101. doi: 10.1111/dom.12323. -
Read More
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, Morrow L, Spitzer H, Demarest K, Rothenberg P.PLoS One. 2014 Sep 30;9(9):e110069. doi: 10.1371/journal.pone.0110069. -
Read More
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
Stein P, Berg JK, Morrow L, Polidori D, Artis E, Rusch S, Vaccaro N, Devineni D.Metabolism. 2014 Jul 9. pii: S0026-0495(14)00198-X. doi: 10.1016/j.metabol.2014.07.003. PMID:25110280 -
Read More
Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?
Krentz AJ, Hompesch M.Pharmaceutical Medicine. 2014 Jun; vol 28, issue 3: 109-117. -
Read More
Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes.
Heise T, Morrow L, Hompesch M, Häring HU, Kapitza C, Abt M, Ramsauer M, Magnone MC, Fuerst-Recktenwald S.Diabetes Obes Metab. 2014 May 14. doi: 10.1111/dom.12317. PMID: 24828020. -
Read More
Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor.
Bailey TS, Ahmann A, Brazg R, Christiansen M, Garg S, Watkins E, Welsh JB, Lee SW.Diabetes Technol Ther. 2014 May;16(5):277-83. doi: 10.1089/dia.2013.0222. PMID:24758729 -
Read More
Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
Nunez DJ, Bush MA, Collins DA, McMullen SL, Gillmor D, Apseloff G, Atiee G, Corsino L, Morrow L, Feldman PL.PLoS One. 2014 Apr 3;9(4):e92494. doi: 10.1371/journal.pone.0092494. PMID:24699248. -
Read More
Pharmacokinetic and Pharmacodynamic Responses of Insulin Degludec in African American, White, and Hispanic/Latino Patients With Type 2 Diabetes Mellitus.
Hompesch M, Morrow L, Watkins E, Roepstorff C, Thomsen HF, Haahr H.Clin Ther. 2014 Feb 5. pii: S0149-2918(13)01158-2. doi: 10.1016/j.clinthera.2013.12.014. -
Read More
Biosimilar Insulins: Basic Considerations.
Heinemann L, Hompesch M.Heinemann L, Hompesch M. -
Read More
Targeting hyperglycaemia with anti-obesity drugs: time for a paradigm shift.
Hompesch M, Krentz AJ.Drugs. 2013 Oct;73(15):1649-51. doi: 10.1007/s40265-013-0123-2. -
Read More
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes.
DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M, Morrow LA, Leslie BR, Boulton DW, Ching A, LaCreta FP, Griffen SC.Diabetes Care. 2013 Oct;36(10):3169-76. doi: 10.2337/dc13-0387. Epub 2013 Jun 4. PMID: 23735727. -
Read More
Insulin resistance: a risk marker for disease and disability in the older person.
Krentz AJ, Viljoen A, Sinclair A.Diabet Med. 2013 May;30(5):535-48. doi: 10.1111/dme.12063. PMID:23173973. -
Read More
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
Kapur A, O Connor-Semmes R, Hussey EK, Dobbins RL, Tao W, Hompesch M, Smith GA, Polli JW, James Jr CD, Mikoshiba I, Nunez DJ.BMC Pharmacol Toxicol. 2013 May 13;14(1):26. PMID: 23668634. -
Read More
Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase.
Morrow L, Muchmore DB, Hompesch M, Ludington EA, Vaughn DE.Diabetes Care. 2013 Feb;36(2):273-5. PMID: 23043164. -
Read More
Developing new drugs for diabetes and cardiometabolic disorders: a changing paradigm. Drugs.
Krentz AJ, Morrow L, Hompesch M.Drugs. 2012 Sep 10;72(13):1709-11. PMID: 22931519. -
Read More
Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.
Norjavaara E, Ericsson H, Sjöberg F, Leonsson-Zachrisson M, Sjöstrand M, Morrow LA, Hompesch M.J Clin Endocrinol Metab. 2012 Sep;97(9):3319-25. PMID: 22723318. -
Read More
Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.
Morrow LA, Leonsson-Zachrisson M, Ericsson H, Wollbratt M, Knutsson M, Hompesch M, Norjavaara E.Diabetes Obes Metab. 2012 Jul 6. doi: 10.1111/j.1463-1326.2012.01661.x. PMID: 22775976. -
Read More
Type 2 diabetes or…? Still looking for a better name.
Krentz, A.J.Diabetes Research and Clinical Practice. 2012;96:259-60. -
Read More
Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J, Ways K, Schwartz S.Diabetes Obes Metab. 2012 Jun;14(6):539-45. doi: 10.1111/j.1463-1326.2012.01558.x. PubMed PMID: 22226086. -
Read More
Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
Hompesch M, Muchmore DB, Morrow L, Ludington E, Vaughn DE.Diabetes Technol Ther. 2012 Mar;14(3):218-24. Epub 2011 Dec 2. PubMed PMID: 22136324. -
Read More
Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects.
de la Peña A, Riddle M, Morrow LA, Jiang HH, Linnebjerg H, Scott A, Win KM, Hompesch M, Mace KF, Jacobson JG, Jackson JA.Diabetes Care. 2011 Dec;34(12):2496-501. Epub 2011 Oct 12. PubMed PMID: 21994429; PubMed Central PMCID: PMC3220843. -
Read More
Short-term metabolic effects of prednisone administration in healthy subjects.
Kauh EA, Mixson LA, Shankar S, McCarthy J, Maridakis V, Morrow L, Heinemann L, Ruddy MK, Herman GA, Kelley DE, Hompesch M.Diabetes Obes Metab. 2011 Nov;13(11):1001-7. doi: 10.1111/j.1463-1326.2011.01432.x. PubMed PMID: 21635675.9. -
Read More
Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers.
Morrow L, Muchmore DB, Ludington EA, Vaughn DE, Hompesch M.Diabetes Technol. Ther. 2011 Oct;13(10):1039-45. PMID: 21714645. -
Read More
Evaluation of a novel continuous glucose measurement device in patients with diabetes mellitus across the glycemic range.
Morrow L, Hompesch M, Tideman AM, Matson J, Dunne N, Pardo S, Parkes JL, Schachner HC, Simmons DA.J Diabetes Sci Technol. 2011 Jul 1;5(4):853-9. PubMed PMID: 21880226; PubMed Central PMCID:PMC3192590. -
Read More
Biosimilar Insulins: How Similar is Similar?
Heinemann, L; Hompesch, M.J Diabetes Sci Technol. 2011;5(3):741-754. -
Read More
Future Treatments for Type 2 Diabetes
Andrew J. Krentz, Marcus HompeschTreatment Strategies Diabetes 2011: 3(1)-: 4149. -
Read More
Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin.
Heinemann L, Hompesch M, Flacke F, Simms P, Pohl R, Albus K, Pfützner A, Steiner S.J Diabetes Sci Technol. 2011 May 1;5(3):681-6. PubMed PMID: 21722583; PubMed Central PMCID: PMC3192634. -
Read More
Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.
Pettis RJ, Ginsberg B, Hirsch L, Sutter D, Keith S, McVey E, Harvey NG, Hompesch M, Nosek L, Kapitza C, Heinemann L.Diabetes Technol Ther. 2011 Apr;13(4):435-42. Epub 2011 Feb 28. PubMed PMID: 21355718. -
Read More
Continuous glucose monitoring using a novel glucose/galactose binding protein: results of a 12-hour feasibility study with the becton dickinson glucose/galactose binding protein sensor.
Judge K, Morrow L, Lastovich AG, Kurisko D, Keith SC, Hartsell J, Roberts B, McVey E, Weidemaier K, Win K, Hompesch M.Diabetes Technol Ther. 2011 Mar;13(3):309-17. PubMed PMID: 21299393. -
Read More
Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase.
Hompesch M, Muchmore DB, Morrow L, Vaughn DE.Diabetes Care. 2011 Mar;34(3):666-8. PubMed PMID: 21273493; PubMed Central PMCID: PMC3041204. -
Read More
Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.
Morrow L, Hompesch M, Guthrie H, Chang D, Chatterjee DJ.Diabetes Obes Metab. 2011 Jan;13(1):75-80. doi: 10.1111/j.1463-1326.2010.01322.x. PubMed PMID: 21114606.
See More...
in cat NOT
Stay Connected
Would you like to receive updates from ProSciento?
View ProSciento’s privacy policy here.
